Alnylam Pharmaceuticals
ALNY
255 hedge funds and large institutions have $4.45B invested in Alnylam Pharmaceuticals in 2016 Q1 according to their latest regulatory filings, with 33 funds opening new positions, 113 increasing their positions, 63 reducing their positions, and 36 closing their positions.
79% more repeat investments, than reductions
Existing positions increased: 113 | Existing positions reduced: 63
29% more funds holding in top 10
Funds holding in top 10: 7 → 9 (+2)
11% more call options, than puts
Call options by funds: $56.3M | Put options by funds: $50.9M
8% less first-time investments, than exits
New positions opened: 33 | Existing positions closed: 36
2% less funds holding
Funds holding: 261 → 255 (-6)
28% less capital invested
Capital invested by funds: $6.22B → $4.45B (-$1.76B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$85.6M |
| 2 |
VAM
Visium Asset Management
New York
|
+$45.9M |
| 3 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$43.4M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$36.5M |
| 5 |
SPC
Slate Path Capital
New York
|
+$27.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Trust Advisors
Wheaton,
Illinois
|
-$50.7M |
| 2 |
Jennison Associates
New York
|
-$34.5M |
| 3 |
UBS AM
Chicago,
Illinois
|
-$17.9M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$17.8M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
-$14.2M |
ALNY Hedge Fund Activity: Q1 2016 in Review
255 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q1 2016, worth a combined $4.45B — down 28% from $6.22B a quarter earlier.
Sellers outnumbered buyers: 36 funds closed out of ALNY and 33 opened new positions — a net loss of 3 holders — while 63 trimmed existing stakes and 113 added.
The largest buyer was Wellington Management Group, adding an estimated $85.6M. The largest seller was First Trust Advisors, cutting an estimated $50.7M.
- 255 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q1 2016, down from 261 in Q4 2015.
- Funds reported $4.45B of Alnylam Pharmaceuticals stock for Q1 2016, down 28% quarter-over-quarter.
- 33 funds opened new Alnylam Pharmaceuticals positions in Q1 2016 and 36 closed out, a net change of -3 holders.
- The largest Alnylam Pharmaceuticals buyer in Q1 2016 was Wellington Management Group, an estimated $85.6M added.
- The largest Alnylam Pharmaceuticals seller in Q1 2016 was First Trust Advisors, an estimated $50.7M sold.
Based on aggregated 13F filings for Q1 2016.